The Division of Oncologic Imaging explores the basic chemical and biochemical mechanisms underlying cancer and how these can be exploited in functional molecular imaging and therapy of cancer to enhance the benefits and quality of patient care. The different groups of the Division focus particularly on research activities which support translational programs according to the precision medicine concept leading to clinical trials.
The current four principal investigators in the Division of Oncologic Imaging perform basic discovery and clinical-based research aimed at the design, synthesis and validation of innovative radiopharmaceuticals to optimize current diagnosis and treatment of cancer. The research programs fall into the categories of radionuclide production, radiopharmaceutical chemistry, radiopharmacy, radiopharmacology, pharmacokinetics, radiation dosimetry, SPECT and PET imaging, and targeted radiotherapy. They also involve a variety of other academic disciplines such as cellular and molecular biology of cancer, health care economics and the initiation and coordination of clinical trials.
Research initiatives are supported by sophisticated basic and clinical research tools that include divers clinical multimodality SPECT and PET imaging instrumentation, a preclinical PET/CT imaging platform, a library of PET and SPECT radiopharmaceuticals for clinical cancer research, fully equipped basic discovery research and clinical production labs with several automated synthesis units for the preparation of innovative radiopharmaceuticals, and two cyclotrons for radionuclide production, including the production of non-standard radioisotopes for special biomedical research applications.
Academic members of the division teach and train graduate students and medical residents in radiopharmaceutical sciences, molecular imaging and nuclear medicine. This also involves teaching of several undergraduate and graduate level courses in oncology, chemistry, pharmacy and radiopharmaceutical sciences and support of the undergraduate M.D. program at the FoMD.